The Global Kratom Coalition (GKC) has expressed its support for the U.S. Food and Drug Administration’s (FDA) recent initiative to conduct clinical research on kratom. This move, led by the newly appointed Deputy Commissioner of the Human Foods Program, James “Jim” Jones, signifies a positive step towards generating robust scientific data on the efficacy and safety of kratom. The FDA’s efforts aim to guide regulatory oversight and provide clearer insights into kratom’s risk profile, potentially altering the industry and consumer landscape significantly. Kratom, a tropical evergreen native to Southeast Asia, has been a subject of debate regarding its regulatory status and safety. The FDA’s clinical research, including a Single Ascending Dose (SAD) study and upcoming Human Abuse Potential (HAP) research, is crucial for understanding kratom’s effects and ensuring consumer safety. The GKC champions access to safe and responsibly sourced kratom products, emphasizing the importance of informed policymaking and regulatory oversight. For more details on this development, read the full article on WRAL.com.
FDA’s New Clinical Research on Kratom Welcomed by Global Kratom Coalition
